Relapsed multiple myeloma demands treatment decisions grounded in current cytogenetic risk profiles, prior therapy history, and access to novel agents. A second opinion helps clarify next-line therapy eligibility and investigational pathways. Key Takeaways Symptomatic relapse with organ damage requires urgent specialist review, while asymptomatic M-protein rise allows scheduled consultations over weeks. Prepare four core documents before consultation: pathology report with FI

Lymphoma patients in India now have unprecedented access to revolutionary CAR-T cell therapy, with indigenous treatments offering 70-83% response rates at costs 80% lower than international alternatives, transforming advanced blood cancer care across the country. TL;DR Dr.Bh arat Patodiya connects lymphoma patients with India's leading CAR-T centers, offering comprehensive evaluation and treatment coordination at ₹30-50 lakhs versus ₹3-4 crores internationally [1] India's in